Licensing Agreement For "Olutasidenib" With Orient Europharma In Taiwan
01/05/2026 07:35
May 1 (Reuters) - Orient Europharma Co Ltd 4120.TWO: KISSEI PHARMACEUTICAL CO LTD: LICENSING AGREEMENT FOR "OLUTASIDENIB" WITH ORIENT EUROPHARMA IN TAIWAN KISSEI PHARMACEUTICAL CO LTD: KISSEI WILL RECEIVE AN UPFRONT PAYMENT AND MILESTONE PAYMENTS BASED ON PROGRESS OF COMMERCIALIZATION IN TAIWAN, AND WILL SUPPLY FORMULATION TO OEP Source text: ID:nTSqa7e05a Further company coverage: 4120.TWO (Reporting by Tokyo Newsroom) ((+81345201189;))
Recent news on Rigel Pharmaceuticals
See all newsU.S. RESEARCH ROUNDUP- Berkshire Hathaway, Exxon Mobil, Honeywell Technologies
Rigel Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary
Rigel Pharmaceuticals Q2 revenue rises on strong product demand
Brief: Rigel Pharmaceuticals - Appoints Alison L. Hannah As Executive Vice President And Chief Medical Officer Effective July 1, 2026 - SEC Filing
Brief: Rigel Announces Closing Of Licensing Agreement For Veppanu (Vepdegestrant)